Fang, Linan
Ly, Dalam
Wang, Si-si
Lee, Jong Bok
Kang, Hyeonjeong
Xu, Hao
Yao, Junlin
Tsao, Ming-sound
Liu, Wei
Zhang, Li
Funding for this research was provided by:
Canadian Cancer Society (grant #704121)
Ontario Research Fund Research Excellence Grant (RE-03-020)
National Natural Science Foundation of China (#81502202)
Scientific Research Foundation in the Science and Technology Development Plan of Jilin Province (20190701043GH, 20190701043GH)
Article History
Received: 26 November 2018
Accepted: 1 March 2019
First Online: 11 March 2019
Ethics approval and consent to participate
: Resected human lung cancer tissues from treatment naïve NSCLC patients were collected upon informed patient consent approved (NO.2016–408) by Ethics Committee, The First Hospital of Jilin University. Heparinized lung cancer patient or healthy donor derived peripheral blood was collected upon informed consent approved (#05–0221) by Research Ethics Board, University Health Network.
: All authors consent for publication.
: Li Zhang is one of the inventors on 7 DNT cell technology-related patents and serves as a scientific consultant for WYZE BIOTECH Co. Ltd. LF, DL, HK, JB and LZ are inventors of patent applications using DNT cells to treat cancers. Other authors declare no conflict of interest.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.